Biotech Belgium SRL
Biotech Belgium reported total assets of 42,133 € at the end of the 2025 financial year (annual accounts filed with the NBB on 08 May 2026).
The score of Biotech Belgium shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +21 % Total assets +13 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Biotech Belgium's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 May 2026
- Year ended 31 Dec 2024filed on 22 Jul 2025
- Year ended 31 Dec 2023filed on 14 Jun 2024
- Year ended 31 Dec 2022filed on 18 Sep 2023
- Year ended 31 Dec 2021filed on 02 Nov 2022
Biotech Belgium's financial analysis
- Solvency76.0%sector median: 31.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Biotech Belgium
Biotech Belgium's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0872.514.604
- VAT number
- BE0872514604
- Peppol
- Registered · 0208:0872514604 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 15 Mar 2005
- Registered office
- 4500 Huy
- Latest accounts
- 2025 · filed on 08 May 2026
- Activity
- Rental and operating of own or leased residential real estate, except social housing (NACE 68201)
Biotech Belgium (SRL) has been based in Huy since 2005, active in: rental and operating of own or leased residential real estate, except social housing. For 2025, it reports a net profit of 1,913 € and equity of 32,017 €; its revenue is not published. Its solvency stands at 76.0%, above the median of its sector (31.5%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Biotech Belgium
Companies in the same business, of comparable size and area, outside its group.
- Giuliano Vastgoed Rental and operating of own or leased real estate Brussels · balance sheet 504,011 €
- Valadri Rental and operating of own or leased real estate Chaudfontaine · balance sheet 44,787 €
- Aceconsult Rental and operating of own or leased real estate Ath · balance sheet 25,906 €
- M.D.C. Rental and operating of own or leased real estate Anderlecht · balance sheet 70,173 €
- KDV Invest Rental and operating of own or leased real estate Nieuwpoort · balance sheet 74,517 €
- TYFN Rental and operating of own or leased real estate Brussels · balance sheet 78,598 €
- Aelter-Forrier Rental and operating of own or leased real estate Zedelgem · balance sheet 85,189 €
- Step by Steppe Rental and operating of own or leased real estate Lasne · balance sheet 92,646 €
Frequently asked questions about Biotech Belgium
What is the revenue of Biotech Belgium?
Biotech Belgium files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Biotech Belgium?
In Belgium, the VAT number is the company number prefixed with BE: BE0872514604 for Biotech Belgium, if the company is VAT-registered. Its company number (CBE) is 0872.514.604.
Where is the registered office of Biotech Belgium?
According to the CBE register, the registered office of Biotech Belgium is in 4500 Huy.
What is the equity of Biotech Belgium?
At the close of the 2025 financial year, the equity of Biotech Belgium amounts to 32,017 €, a solvency of 76.0% of total assets.
Who manages Biotech Belgium?
The register lists 1 active mandates at Biotech Belgium. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Biotech Belgium
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →